Acute Myeloid Leukemia
Novel Approaches and New Therapeutics
Robert Signer (UCSD)
Kentsom Lam (UCSD)
AML is an aggressive and deadly cancer of white blood cells. Traditional chemotherapy has been used for the past 50 years, yet the survival rate is only 29%. This proposal is based on emerging evidence that AML cells are sensitive to drugs that interfere with the intracellular processes of “taking out the trash” and “recycling” (as known as proteostasis). The goal is to elucidate new strategies that can be used to more effectively treat AML and other cancers.
“Curebound’s support is instrumental to expanding our studies to determine if this approach holds the key to eliminating AML within the body. This vital research has the potential to revolutionize AML treatment and pave the way for new therapies benefiting all cancer patients. Curebound’s investment is propelling our mission to transform the lives of AML patients and make a lasting impact on cancer research.” - Robert Signer, PhD